Adaptive Biotechnologies officer proposes $192K sale

Her listed prior sales include four transactions identified as 10b5-1 sales, dated July 16 through September 15, 2026.

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp officer Susan Bobulsky reported a proposed sale of 6,444 common shares, with an aggregate market value of $192,288.96 and an approximate sale date of October 6, 2026. The shares were acquired upon the vesting of restricted stock units during the period from March 4, 2023, through March 4, 2024.

Her past-three-month sales identified as 10b5-1 sales were 5,000 shares on July 16, 2026; 1,299 shares on July 30, 2026; 3,000 shares on August 10, 2026; and 1,195 shares on September 15, 2026. The issuer’s common shares outstanding are listed as 159,595,842.

Key Figures

Proposed sale: 6,444 shares Aggregate market value: $192,288.96 Common shares outstanding: 159,595,842 shares +4 more

7 metrics

Proposed sale 6,444 shares Common shares

Aggregate market value $192,288.96 Proposed sale

Common shares outstanding 159,595,842 shares Issuer shares outstanding

Past sale 5,000 shares July 16, 2026

Past sale 1,299 shares July 30, 2026

Past sale 3,000 shares August 10, 2026

Past sale 1,195 shares September 15, 2026

Key Terms

restricted stock units, 10b5-1 Sales, Rule 144, aggregate market value

4 terms

restricted stock units technical

"acquired upon the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

10b5-1 Sales regulatory

"10b5-1 Sales for SUSAN BOBULSKY"

10b5-1 sales are pre-arranged stock-trading plans that let company insiders automatically buy or sell shares according to a fixed schedule or formula, even if they later learn confidential information. Think of it as setting up an automatic thermostat for trades: it creates a clear, documented path that can protect insiders from insider-trading accusations and gives investors a signal about predictable insider activity—though it can also simply be a way for insiders to diversify or raise cash.

Rule 144 regulatory

"paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

aggregate market value financial

"Aggregate market value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ADPT shares did Susan Bobulsky propose to sell?

Susan Bobulsky reported a proposed sale of 6,444 common shares, with an aggregate market value of $192,288.96 and an approximate sale date of October 6, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/06/2026 - 04:23 PM Accepted by SEC EDGAR 10/06/2026 - 04:22 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001820885
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ADAPTIVE BIOTECHNOLOGIES CORPORATION
SEC File Number	001-38957
Address of Issuer	1165 Eastlake Avenue East Seattle WASHINGTON 98109
Phone	2066590067
Name of Person for Whose Account the Securities are To Be Sold	SUSAN BOBULSKY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	6444	192288.96	159595842	10/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/04/2023	Restricted Stock Units	Issuer			6444	03/04/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for SUSAN BOBULSKY 1165 Eastlake Avenue East Seattle WA 98109	Common	09/15/2026	1195	32265.00
10b5-1 Sales for SUSAN BOBULSKY 1165 Eastlake Avenue East Seattle WA 98109	Common	08/10/2026	3000	75000.00
10b5-1 Sales for SUSAN BOBULSKY 1165 Eastlake Avenue East Seattle WA 98109	Common	07/30/2026	1299	31176.00
10b5-1 Sales for SUSAN BOBULSKY 1165 Eastlake Avenue East Seattle WA 98109	Common	07/16/2026	5000	115000.00

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted stock units during the period of 3/4/2023 through 3/4/2024
Date of Notice	10/06/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/16/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Susan Bobulsky
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)